U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

First Page		Document Content
Combination drugs Asthma Epidemiology Fluticasone/salmeterol Zileuton Omalizumab Cromoglicic acid Clinical trial Pulmonology Medicine Respiratory therapy		U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 757,14 KB Share Document on Facebook

	Modificadores de Leucotrienos (Accolate®, Singulair ®, Zileuton ®) DocID: 19Prx - View Document
	Leukotriene Modifiers (Accolate®, Singulair®, Zileuton®) What are They? DocID: 19NXJ - View Document
	PDF Document DocID: TP1t - View Document
	Clin Pharmacokinet DOI[removed]s40262[removed]ORIGINAL RESEARCH ARTICLE Determination of an Optimal Dosing Regimen for Fexinidazole, DocID: RMYF - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JUXTAPID safely and effectively. See full prescribing information for JUXTAPID. JUXTAPID® (lomitapide) capsules, fo DocID: HgYQ - View Document